T-1399 Tofacitinib, Citrate Salt, >99%

Synonyms : [CP-690550] [CP-690550 Citrate] [Tasocitinib]

Related Terms : [Xeljanz]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 52
  • 45
  • 40
  • 5,800
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 75
  • 66
  • 58
  • 8,400
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 98
  • 86
  • 76
  • 11,000
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 164
  • 144
  • 127
  • 18,400
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 333
  • 293
  • 259
  • 37,300
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 497
  • 437
  • 387
  • 55,600
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 834
  • 733
  • 649
  • 93,400
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 1,290
  • 1,135
  • 1,004
  • 144,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 504.49
  • C16H20N6O•C6H8O7
  • [540737-29-9]
  • M.I. 14: 10489

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 6 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Certificate of Analysis

  • This is the citrate salt form of tofacitinib. See Tofacitinib, Free Base (Cat. No. T-1377) for further technical information. It is this citrate salt form, not the free base, that is used in the formulation of tofacitinib for in vivo use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
  • Tofacitinib citrate is the active ingredient in the drug product sold under the trade name Xeljanz®. This drug is currently approved in at least one country for use in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. THE TOFACITINIB, CITRATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT XELJANZ®, AND IS NOT FOR HUMAN USE.
69